Novo Nordisk Rebrands as ‘Novo’ in Push to Win Back Obesity Market (NVO:NYSE)
The Danish drugmaker said the change aims to rebuild trust and regain obesity-market share after shares fell about 15% this year, it said.
- On Monday, the Danish firm Novo Nordisk announced it would embrace "Novo" as its new brand, aiming to signal a shift toward greater focus, speed, and impact in its corporate culture.
- The Danish drugmaker, formed by the 1989 merger of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium, is grappling with stiff competition from Eli Lilly and investor pressure to deliver new growth.
- Market data shows Novo lags in the obesity space with 38.8% market share compared to Lilly's 60.9%, while shares have dropped about 15% this year despite the successful launch of the oral version of Wegovy.
- Alongside the name change, the company announced a broader rebrand focused on the phrase "Lasting Health Starts Now," which promotes immediate progress toward long-term well-being to "create greater value for all stakeholders."
- Following the recent cancellation of three trials for an experimental cardiovascular drug, strategy changes will be detailed during the Capital Markets Day event on Sept. 21.
34 Articles
34 Articles
Reformatorisch Dagblad
The Danish pharmaceutical company Novo Nordisk, known for the medicines Wegovy and Ozempic, is going to change its name to Novo. According to the company, this is intended to increase recognizability among consumers. The corporate logo featuring the bull is also being modified.
Ozempic-maker Novo Nordisk slims down to ‘Novo’
Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced on Monday a name change to just Novo, hoping it will be more “memorable and relevant” for clients. The rebrand comes ahead of a strategic presentation on September 21, when executives are to lay out their plan for “a faster, more competitive and increasingly consumer-driven market”. The company is battling fierce competition in the anti-obesity se…
The pharmaceutical giant will now be called Novo only. The Apis bull in the logo will also be reversed.
Coverage Details
Bias Distribution
- 42% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
